MIRA Pharmaceuticals, Inc. , a leading pre-clinical-stage pharmaceutical development company, announces compelling new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, ...
GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and ...
This is the most recent version of the national Cancer Drugs Fund list, and replaces any earlier versions. It contains updates to the previous list, as well as new drugs and indications which have ...